Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

DR.REDDY'S LABORATORIES LTD (DRREDDY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CET

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at [email protected]/ +91-40-66834297
Saunak Savla at [email protected]/ +91-40-49002135
Milan Kalawadia (USA) at [email protected]/ +1 908-203-4931

Media:
S Rajan at [email protected]/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
02/19Oncology Biosimilar Market to Grow at a High CAGR by 2025 - Top Players Inclu..
AQ
02/19Oncology Biosimilar Market to Grow at a High CAGR by 2025 – Top Players..
AQ
02/15Indivior bets on $1 billion anti-addiction shot as legal bill weighs
RE
02/15INDIAN ADRS : Tata Motors, Wipro gain 2%
AQ
02/14INDIAN ADRS : ICICI Bank, Infosys, Tata Motors down
AQ
02/14+50% CAGR TO BE ACHIEVED BY BIOSIMIL : Global Biosimilars Market – Know In..
AQ
02/10INDIAN ADRS : Dr Reddy`s Lab gains 3%, Wipro rises 2.3%
AQ
02/09INDIAN ADRS : ICICI Bank, HDFC Bank down 3%, Wipro, Tata Motors slip 2%
AQ
02/09DR REDDY LABORATORIES : INDIVIOR FILES LAWSUIT AGAINST Dr REDDY'S FOR INFRINGING..
AQ
02/09DR REDDY LABORATORIES : Drl recalls over 80,000 bottles of atorvastatin from us
AQ
More news
News from SeekingAlpha
02/19Warren Buffett's Berkshire Claims $358 Million Investment In Teva, But That D.. 
02/02Generic drug makers in the red on market's down day 
02/02Dr. Reddy's launches generic Xenazine in U.S. 
01/25Dr. Reddy's Laboratories Limited 2018 Q3 - Results - Earnings Call Slides 
01/25Dr. Reddy's Laboratories' (RDY) Management on Q3 2018 Results - Earnings Call.. 
Financials ( INR)
Sales 2018 144 B
EBIT 2018 15 089 M
Net income 2018 11 240 M
Debt 2018 31 006 M
Yield 2018 0,82%
P/E ratio 2018 32,01
P/E ratio 2019 19,28
EV / Sales 2018 2,76x
EV / Sales 2019 2,38x
Capitalization 367 B
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Technical analysis trends DR.REDDY'S LABORATORIES LT
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 42
Average target price 2 592  INR
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIES LTD-8.96%5 702
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572